596095-91-9

Basic information

• Product Name: Butanoic acid, 4-chloro-3-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]-4-oxo-, Methyl ester, (3S)-
• Synonyms: Butanoic acid, 4-chloro-3-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]-4-oxo-, Methyl ester, (3S)-;(S)-methyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-chloro-4-oxobutanoate
• CAS NO: 596095-91-9
• Molecular Formula: C₂₀H₁₈ClNO₅
• Molecular Weight: 387.81362
• Mol File: 596095-91-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 572.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.323±0.06 g/cm3(Predicted)
• PKA: 9.50±0.46(Predicted)
• CAS DataBase Reference: Butanoic acid, 4-chloro-3-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]-4-oxo-, Methyl ester, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-chloro-3-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]-4-oxo-, Methyl ester, (3S)-(596095-91-9)
• EPA Substance Registry System: Butanoic acid, 4-chloro-3-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]-4-oxo-, Methyl ester, (3S)-(596095-91-9)

Safety Data

• Hazardous Substances Data: 596095-91-9(Hazardous Substances Data)

Upstream product

• 145038-53-5 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methoxy-4-oxobutanoic acid 

Downstream Products

• 1300019-41-3 methyl [(3S)-2-[(1Z)-2-acetylhydrazino]-5-(4-chlorophenyl)-7-(methyloxy)-3H-1,4-benzodiazepin-3-yl]acetate 
• 1300019-41-3 methyl [(3S)-2-[(1Z)-2-acetylhydrazino]-5-(4-chlorophenyl)-7-(methyloxy)-3H-1,4-benzodiazepin-3-yl]acetate 
• 1300019-40-2 methyl 2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzol[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate 
• 1300019-41-3 methyl 2-[(3S,2Z)-2-(acetylhydrazono)-5-(4-chlorophenyl)-7-(methyloxy)-1,3-dihydro-1,4-benzodiazepin-3-yl]acetate 
• 1300019-43-5 (S)-methyl 2-(5-(4-chlorophenyl)-7-methoxy-2-thioxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetate 
• 1300019-46-8 (S)-methyl 2-(5-(4-chlorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetate 
• 1300019-48-0 methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate 

Relevant articles and documents

THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE

The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo

Evaluation of linker length effects on a BET bromodomain probe

Fueled by the therapeutic potential of the epigenetic machinery, BET bromodomains have seen high interest as drug targets. Herein, we introduce different linkers to a BET bromodomain benzodiazepine ligand (I-BET762) to gauge its implications in the develo

Solid-phase synthesis of tetrahydropyridazinedione-constrained peptides

The design and solid-phase synthesis of tetrahydropyridazine-3,6-dione (Tpd) peptidomimetics derived from backbone-aminated peptides is reported. The described protocol features the synthesis of chiral α-hydrazino acids suitable for chemoselective incorporation into growing peptide chains. Acid-catalyzed cyclization to form the Tpd ring during cleavage affords the target peptidomimetics in good yield and purity. The scope of Tpd incorporation is demonstrated through the synthesis of constrained peptides featuring nucleophilic/electrophilic side chains and sterically encumbered α-substituted hydrazino acid residues. (Chemical Equation Presented).